Predicine to Present 9 Liquid Biopsy Studies at ASCO 2024

HAYWARD, Calif., May 21, 2024 — Predicine, Inc., a leader in precision oncology, has disclosed that it will present findings from nine circulating tumor DNA (ctDNA) studies at the upcoming American Society of Clinical Oncology (ASCO) 2024 conference. These studies highlight the clinical applications of Predicine’s genomic and epigenomic liquid biopsy technologies, which are geared toward patient selection, disease monitoring, and investigations into drug resistance mechanisms.

The upcoming data showcases the practical utility of Predicine’s advanced liquid biopsy solutions in personalized cancer treatment, clinical trials, and the development of Companion Diagnostics (CDx). The studies to be presented underscore the strengths of Predicine’s personalized PredicineBEACON™ and methylation-based PredicineALERT™ MRD. These technologies offer significant advantages in biomarker discovery, therapy selection, minimal residual disease (MRD) monitoring, and analyses of drug resistance mechanisms.

Predicine’s oral presentation will take place on Saturday, June 1, from 1:30 pm to 4:30 pm, where Jian Li will discuss a Phase 1 study. This study focuses on the small-molecule PD-L1 inhibitor INCB099280, detailing updated safety, efficacy, and pharmacokinetics results in patients with select advanced solid tumors. This presentation will feature the PredicineCARE™ product.

Additionally, Predicine will showcase multiple poster presentations across the conference dates. On Saturday, June 1, from 9:00 am to 12:00 pm, abstracts include:

- The use of Glioma monitoring via longitudinal intracranial cerebrospinal fluid cell-free DNA, utilizing PredicineCARE™ and PredicineSCORE™.
- An ultra-sensitive ctDNA NGS assay for detection and monitoring in HR-positive, HER2-negative breast cancer, using PredicineCARE™ Ultra.

On Sunday, June 2, from 9:00 pm to 12:00 pm, the presentations include:

- Non-invasive detection of urothelial carcinoma through ensembled methylation profiles and fragmentomic patterns in urinary cell-free DNA, using PredicineEPIC™.
- A real-world study on urine-based NGS liquid biopsy in organ preservation therapy for muscle-invasive bladder cancer (MIBC), employing PredicineBEACON™ and PredicineALERT™.
- Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy, utilizing PredicineBEACON™.
- A Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST), featuring PredicineCARE™.

On Monday, June 3, from 1:30 pm to 4:30 pm, the presentations will cover:

- A high-dose furmonertinib study in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases, using PredicineEPIC™.
- Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC), utilizing PredicineBEACON™.

Predicine will have a booth at ASCO 2024 (#14105) where attendees can engage in discussions about these innovative studies and explore collaboration opportunities. Predicine’s liquid biopsy solutions are designed to be accessible and affordable for global clinical trials, CDx development, and patient testing across the US, EU, China, and beyond.

Predicine is dedicated to advancing precision medicine in oncology through its proprietary cell-free DNA and RNA-based liquid biopsy technology. This approach supports minimally invasive molecular diagnostics for treatment selection, therapy monitoring, minimal residual disease, and early cancer detection. With operations in Silicon Valley, Houston, Chicago, and Shanghai, Predicine collaborates globally with leading biopharma companies, institutions, and governments to enhance personalized healthcare.